1. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy;Aloisi;Lancet Neurol.,2023
2. Atara biotherapeutics announces primary analysis data from phase 2 EMBOLD clinical trial of ATA188 in non-active progressive multiple sclerosis;[WWW Document]. Atara Biotherapeutics.,2023
3. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis;Bar-Or;Mult. Scle. J. Sage Publicat. Ltd 1 Olivers Yard,2022
4. Longitudinal monitoring of plasma GFAP and TCRβ-clonotypes following ATA188 adoptive T-Cell therapy;Bhat;16th ISNI Congress Book of Abstracts,2023
5. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway;Boussiotis;N. Engl. J. Med.,2016